Logo image of DRMA

DERMATA THERAPEUTICS INC (DRMA) Stock Fundamental Analysis

NASDAQ:DRMA - Nasdaq - US2498454055 - Common Stock - Currency: USD

0.76  -0.01 (-1.32%)

Fundamental Rating

2

Taking everything into account, DRMA scores 2 out of 10 in our fundamental rating. DRMA was compared to 561 industry peers in the Biotechnology industry. DRMA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. DRMA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

DRMA had negative earnings in the past year.
In the past year DRMA has reported a negative cash flow from operations.
In the past 5 years DRMA always reported negative net income.
DRMA had a negative operating cash flow in each of the past 5 years.
DRMA Yearly Net Income VS EBIT VS OCF VS FCFDRMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of DRMA (-347.70%) is worse than 96.08% of its industry peers.
The Return On Equity of DRMA (-787.11%) is worse than 82.53% of its industry peers.
Industry RankSector Rank
ROA -347.7%
ROE -787.11%
ROIC N/A
ROA(3y)-194.6%
ROA(5y)-241.76%
ROE(3y)-356.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DRMA Yearly ROA, ROE, ROICDRMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 1K -1K 2K

1.3 Margins

DRMA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DRMA Yearly Profit, Operating, Gross MarginsDRMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, DRMA has more shares outstanding
Compared to 5 years ago, DRMA has more shares outstanding
There is no outstanding debt for DRMA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DRMA Yearly Shares OutstandingDRMA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
DRMA Yearly Total Debt VS Total AssetsDRMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -35.76, we must say that DRMA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -35.76, DRMA is doing worse than 92.69% of the companies in the same industry.
DRMA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -35.76
ROIC/WACCN/A
WACCN/A
DRMA Yearly LT Debt VS Equity VS FCFDRMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

DRMA has a Current Ratio of 1.79. This is a normal value and indicates that DRMA is financially healthy and should not expect problems in meeting its short term obligations.
DRMA has a Current ratio of 1.79. This is in the lower half of the industry: DRMA underperforms 78.43% of its industry peers.
DRMA has a Quick Ratio of 1.79. This is a normal value and indicates that DRMA is financially healthy and should not expect problems in meeting its short term obligations.
DRMA has a worse Quick ratio (1.79) than 76.65% of its industry peers.
Industry RankSector Rank
Current Ratio 1.79
Quick Ratio 1.79
DRMA Yearly Current Assets VS Current LiabilitesDRMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 72.00% over the past year.
EPS 1Y (TTM)72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 39.00% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y93.35%
EPS Next 2Y39%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DRMA Yearly EPS VS EstimatesDRMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -200 -400 -600

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DRMA. In the last year negative earnings were reported.
Also next year DRMA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DRMA Price Earnings VS Forward Price EarningsDRMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DRMA Per share dataDRMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

DRMA's earnings are expected to grow with 39.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

DRMA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DERMATA THERAPEUTICS INC

NASDAQ:DRMA (5/22/2025, 2:10:07 PM)

0.76

-0.01 (-1.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-17 2025-03-17/amc
Earnings (Next)N/A N/A
Inst Owners1.01%
Inst Owner ChangeN/A
Ins Owners5.23%
Ins Owner Change8.17%
Market Cap4.58M
Analysts82.86
Price Target6.12 (705.26%)
Short Float %5.53%
Short Ratio0.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.2%
Min EPS beat(2)-34.64%
Max EPS beat(2)24.24%
EPS beat(4)1
Avg EPS beat(4)-11.63%
Min EPS beat(4)-34.64%
Max EPS beat(4)24.24%
EPS beat(8)5
Avg EPS beat(8)11.49%
EPS beat(12)9
Avg EPS beat(12)14.57%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)61.21%
EPS NY rev (1m)0%
EPS NY rev (3m)60.63%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.94
P/tB 2.94
EV/EBITDA N/A
EPS(TTM)-15.33
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-1.85
FCFYN/A
OCF(TTM)-1.85
OCFYN/A
SpS0
BVpS0.26
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -347.7%
ROE -787.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-194.6%
ROA(5y)-241.76%
ROE(3y)-356.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.79
Quick Ratio 1.79
Altman-Z -35.76
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.6%
EPS Next Y93.35%
EPS Next 2Y39%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-55.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-74.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-74.18%
OCF growth 3YN/A
OCF growth 5YN/A